PowerShares Dynamic Biotechnology & Genome Portfolio: (PBE)
(Real Time Quote from BATS) As of May 22, 2018 03:58 PM ET
$50.64 USD
+0.14 (0.28%)
Volume: 21,680
Zacks ETF Rank 2 - Buy 2
This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:
| Zacks Rank | Definition |
|---|---|
| 1 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 4 | Sell |
| 5 | Strong Sell |
See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs
ETF Quote Details
| Previous Close | 50.51 |
| Open | 50.76 |
| Bid | 50.00 |
| Ask | 51.00 |
| Day Low-High | 50.64-50.95 |
| 52wk Low-High | 41.36-54.28 |
| Volume | 21,680 |
| NAV (month end) | 48.02 |
| Premium (+)/Discount (-) (month end) | +2.49 |
ETF Expense Ratio
| Expense Ratio | 0.58% |
| Dividend (Yield) | $0.22 (0.43%) |
| Issuer | INVESCO POWERSHARES |
Benchmark for PBE
DYNAMIC BIOTECHNOLOGY-GENOME INTELLIDEX
This is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
Fund Summary for PBE
POWERSHARES DYNAMIC BIOTECHNOLOGY-GENOME
It is based on the Dynamic Biotechnology & Genome Intellidex Index. It invests at least 90% of its total assets in common stocks that comprise the Index which provides capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.